Walter M. Stadler to Receptor, Fibroblast Growth Factor, Type 3
This is a "connection" page, showing publications Walter M. Stadler has written about Receptor, Fibroblast Growth Factor, Type 3.
Connection Strength
0.156
-
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
Score: 0.122
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.034